Stenabolic, known by its research name SR-9009, was developed by Professor Thomas Burris at The Scripps Research Institute. SR-9009 has been a subject of interest among medical researchers for its prospective applications in managing metabolic syndromes, enhancing endurance, and contributing to weight loss. This drug is a synthetic molecule that modulates REV-ERB proteins.
REV-ERBs are nuclear receptors, and they are found in various tissues throughout the body. These receptors are particularly prevalent in metabolic tissues such as the liver, adipose tissue (fat cells), and muscle. The distribution of REVERBs in these tissues underscores their role in regulating metabolic processes. SR-9009 modulates the action of these receptors, leading to the desired outcome of enhancing performance.
This mode of action means that SR-9009 is not a SARM. Despite being used along with SARMs, it does not affect the Androgen Receptors.
Forum users adding Stenabolic to their cutting cycles report the following positive effects:
- Bodyfat loss
- Increase in the metabolic rate
- Increase in Endurance
- Decrease of inflammation
- Decrease in bad cholesterol
Mechanism of Action
Targeting REV-ERBs, it functions by modulating REV-ERB proteins (REV-ERBα and REV-ERBβ), which play a pivotal role in regulating the expression of genes implicated in lipid and glucose metabolism, thereby influencing circadian rhythms and metabolic output.
